Strategic Objectives
• Master the legal frameworks of the Orphan Drug Act.
• Navigate the complex intersection of tax credits and grants.
• Understand how market exclusivity creates artificial monopolies for good.
• Learn to design fiscal policies that bridge the gap between science and profit.
The Core Challenge
In a market-driven economy, pharmaceutical giants naturally ignore rare diseases because the patient populations are too small to justify the R&D costs.
01
The Economic Void
02
Defining the Orphan
03
The Legislative Catalyst
04
Monopoly by Design
05
The Cost of Discovery
06
Taxation as a Tool
07
Public Seed Money
08
The Regulatory Bridge
09
Accelerated Pathways
10
Intellectual Property Strategy
11
Pricing the Invaluable
12
The European Model
13
Venture Capital Dynamics
14
Priority Review Vouchers
15
Off-Label Economics
16
Health Technology Assessment
17
Public-Private Partnerships
18
The Payer's Dilemma
19
Corporate Social Responsibility
20
The Future of Fiscal Policy
21
Global Equity in Access
Explore Research Ecosystem
Available eBook Editions
Arabic
English
French
German
Italian
Japanese
Korean
Portuguese
Spanish
